Stock Analysis
Scholar Rock Holding Corporation (SRRK) Stock Analysis
Scholar Rock Holding Corporation (SRRK) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Scholar Rock Holding Corporation (SRRK) currently has an AIQ Score of 39/100, indicating a bearish setup. Momentum is the strongest factor at 54/100. Quality is the weakest current factor at 14/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
SRRK at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $43.21 |
| AIQ Score | 39/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Sell |
| Market Cap | $5.72B |
| P/E Ratio (TTM) | -13.42 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.81 |
| Revenue (Q3 FY2026) | $570K |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.12 |
| Volume | 623.56K |
| 52-week range | $29.35-$61.76 |
| RSI 14 | 45.31 |
| 50-Day SMA | $46.13 |
| 200-Day SMA | $48.24 |
| Analyst Price Target | $71.30 |
| Next Earnings | Mar 2, 2027 |
SRRKScholar Rock Holding Corporation
Healthcare / Biotechnology
Low Priority
Above Peers
Latest quote
- Momentum54
- Value—
- Quality14
- Risk resilience52
- Sentiment—
SRRK Stock Analysis Summary
Scholar Rock Holding Corporation (SRRK) currently has an AIQ Score of 39/100, indicating a bearish setup. Momentum is the strongest factor at 54/100. Quality is the weakest current factor at 14/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, SRRK has AIQ Score of 39/100 with Momentum base of 54/100 and fading Quality at 14/100. Wait for component alignment before adding exposure.
Momentum (54/100) leads while Quality (14/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 0.10% stock move · SRRK classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is SRRK Bullish or Bearish Right Now?
SRRK currently has a bearish overall setup. Momentum is the strongest factor at 54/100, while Quality is weakest at 14/100. The current evidence suggests a bearish setup.
- - Analyst target implies +65.03% upside from the latest quote.
- - Price is -10.43% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (26 vs 14).
Current Consensus
SRRK's Technical Analysis Consensus is currently Sell, with 14 buy, 6 neutral, and 26 sell votes. SRRK's 14-day RSI is 45.31, which places the stock in a neutral momentum range. SRRK's beta is 1.12, indicating market sensitivity broadly in line with the market.
What Changed in SRRK?
The largest recent change in SRRK is Quality moving down by 15.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the SRRK Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
SRRK Decision Framework
Public evidence layers, setup checks, and risk context for Scholar Rock Holding Corporation.
Scholar Rock Holding Corporation (SRRK) Stock Analysis
Scholar Rock Holding Corporation has an AIQ Score of 39/100 in a Bearish regime. Momentum is strongest at 54/100. Beta is 1.12, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | SRRK is in a Bearish AIQ regime with score 39/100. |
| Signal Conflict | The primary conflict is that momentum leads at 54/100 while quality lags at 14/100. |
| Factor Evidence | Momentum 54/100 · Quality 14/100 · Risk 52/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 54/100.
Momentum is 54/100 and RSI (14) is 45.3.
SRRK is in a Bearish regime at 39/100.
Risk factor is 52/100 with beta 1.12 and annual volatility 57.45%.
Current conflict: momentum leads at 54/100 while quality lags at 14/100.
SRRK Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
SRRK Fundamentals
SRRK valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
SRRK Technical Analysis
SRRK technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
SRRK Stock Catalysts
Track SRRK earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
SRRK Dividend Analysis
SRRK dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
SRRK Financial Data
SRRK revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
SRRK Risk Analysis
SRRK volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
SRRK Stock News
SRRK stock news, market tone, recent headlines, and catalyst context.
SRRK vs Biotechnology Peers
Current peer cohort: SRRK · STOK · SYRE · TARS · TGTX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| SRRK Current stock | 39/100 | — | 54/100 | 52/100 | 0.84 | 57.45% | Current |
| STOK Stoke Therapeutics, Inc. | 42/100 | 22/100 | 47/100 | 59/100 | 0.23 | 53.19% | SRRK vs STOK |
| SYRE Spyre Therapeutics, Inc. | 64/100 | 44/100 | 81/100 | 53/100 | 2.57 | 66.66% | SRRK vs SYRE |
| TARS Tarsus Pharmaceuticals, Inc. | 65/100 | 75/100 | 76/100 | 59/100 | 0.36 | 45.02% | SRRK vs TARS |
| TGTX TG Therapeutics, Inc. | 76/100 | 65/100 | 93/100 | 63/100 | 1.74 | 46.06% | SRRK vs TGTX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for SRRK: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching SRRK
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for SRRK
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
SRRK Stock FAQ
What is SRRK stock price today?
Scholar Rock Holding Corporation's current stock price is $43.21. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is SRRK bullish or bearish right now?
SRRK's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is SRRK's market cap?
SRRK's market cap is $5.72B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is SRRK's current P/E ratio?
SRRK's current P/E ratio is -13.42 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is SRRK's RSI?
SRRK's 14-day RSI is 45.31 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is SRRK above its 50-day and 200-day moving averages?
SRRK is -6.34% from its 50-day SMA and -10.43% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is SRRK's next earnings date?
SRRK's next earnings date is currently listed as Mar 2, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does SRRK pay a dividend?
SRRK's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.